TradeFlare's AI research teams analysed DYN on 16 market nights between April 20, 2026 and October 12, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| October 12, 2026 | HOLD | $16.64 | — / — | not yet | not yet | The current setup does not warrant a BUY, and the market regime is neutral, suggesting a cautious approach. |
| October 7, 2026 | HOLD | $15.40 | $17.71 / $13.09 | not yet | not yet | The current setup does not meet the minimum R/R requirement for a BUY. |
| September 4, 2026 | HOLD | $24.95 | $29.94 / $21.21 | -23.7% | -36.4% | The stock is showing signs of a potential oversold bounce, but the technicals are mixed and there's significant risk. |
| September 3, 2026 | BUY | $25.14 | $27.65 / $21.36 | -27.0% | -39.1% | The fundamental catalyst (FDA priority review) has a longer-term timeline, but technical signals suggest a near-term bounce. |
| September 2, 2026 | BUY | $25.10 | $29.62 / $21.34 | -26.7% | -37.1% | The technical setup suggests a short-term bounce opportunity, supported by fundamental and sentiment tailwinds. |
| August 31, 2026 | HOLD | $25.07 | — / — | -20.1% | -36.3% | The stock is in a neutral market environment, and while fundamentals are bullish, technicals are neutral and risk is high, preventing a buy recommendation. |
| July 27, 2026 | BUY | $24.44 | $28.00 / $20.77 | -1.5% | +1.4% | The stock is breaking out on high volume and has strong technical and sentiment indicators, suggesting a short-to-medium term upward trend. |
| June 10, 2026 | BUY | $17.92 | — / — | +8.7% | +32.5% | The current market regime and stock-specific factors do not support a buy decision. |
| May 29, 2026 | BUY | $18.56 | — / — | -11.8% | +10.0% | Insider buying from Posner Brian S provides a high-conviction fundamental signal. |
| May 27, 2026 | BUY | $18.15 | — / — | -0.9% | +13.5% | Initiation of late-stage clinical trials for DYN-201. |
| May 25, 2026 | BUY | $17.37 | — / — | -5.0% | +12.0% | The market regime is neutral, and while there's insider buying, the fundamental and technical analyses present significant headwinds. |
| April 30, 2026 | BUY | $17.41 | — / — | -0.1% | +10.1% | KEY CATALYSTS: |
| April 29, 2026 | BUY | $18.16 | — / — | +8.2% | +6.6% | The current market regime is neutral, and DYN's technicals are also neutral, indicating a lack of clear directional conviction. |
| April 28, 2026 | BUY | $18.04 | — / — | -3.8% | +0.0% | Positive clinical trial updates or data releases. |
| April 27, 2026 | HOLD | $18.26 | — / — | -1.8% | +0.6% | Positive clinical trial data readouts for DYN's lead programs. |
| April 20, 2026 | BUY | $20.41 | $23.93 / $19.33 | -9.9% | -17.4% | Expecting the price to reach the resistance level within a few weeks based on the bullish market and insider buying. |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.